Healsun Biopharm, a high-tech antibody/recombinant protein CDMO company, will continue to promote its biopharma CDMO services and develop more innovative technologies with the fresh proceeds.
Healsun Biopharm (Chinese: 皓阳生物), focusing on providing antibody/recombinant protein CDMO services, completed the Series B round of financing worth nearly CNY 250 million recently. The round was led by Shanghai Biomedical Fund (Chinese: 上海生物医药基金), with the participation from Oriental Jiafu Asset Management (Chinese:东方嘉富), Haitong Capital (Chinese: 海通开元), Xinghua Dingli (Chinese: 兴华鼎立) and the existing investors Haibang Capital (Chinese: 海邦投资) and Yinxinggu Capital (Chinese: 银杏谷资本). Instant Capital (Chinese: 刹那资本) is the exclusive financial advisor for this round.
The funds will be used to improve the staff team, build a 2000L production line and solve the CMC difficulties of exosomes, mRNA and AAV.
Founded in 2015, Healsun Biopharma is dedicated to offering end-to-end service by multiple platforms from early developability assessments, stable cell line construction, culture medium customization, process development (including ADC) to pilot production, IND application and clinical production. The company's recombinant GLP-1 receptor agonist injection project was granted the NMPA clinical trial implied license at the beginning of last year, becoming the first dulaglutide biosimilar drug to receive clinical trial approval in China. Healsun has completed 6 IND applications in China, the United States and Australia this year.
The company's competitors include TransMed (Chinese: 创迈生物), Foster Bio (Chinese: 赋成生物) and SIGO Biologics (Chinese: 晟国医药).